A Phase 2 interventional study of Aroxxen in Coronary Artery Disease, sponsored by Research Institute of Geroprotective Technologies. Recruiting at 1 site in Russia. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-05-06.
Sponsored by Research Institute of Geroprotective Technologies · Phase 2, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Coronary Artery Disease with a site in Russia — 16 open to participants now, 17 under way, none of them phase 3. Coronary Artery Disease · Russia.
Among the 26 studies in Coronary Artery Disease with a site in Russia, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is one of 7 that started in 2026, is one of 3 in phase 2, reaches primary completion later than 2 of the 16 other live ones, and was the 18th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →16 of the 26 studies in Coronary Artery Disease with a site in Russia are open now. Recruiting first, the newest first:
Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health · Sites in Russia
Ages 18+
Tomsk Cardiology Research Institute · Sites in Russia
Ages 18+ · Women only
Lomonosov Moscow State University Medical Research and Educational Center · Sites in Russia
Ages 40–65 · Men only
Tomsk National Research Medical Center of the Russian Academy of Sciences · Sites in Russia
Primorsky Regional General Hospital #1 · Sites in Russia
Ages 18–75
A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 50 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 7 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 123 across 3,011 interventional studies indexed under Coronary Artery Disease.
Median enrollment 113 across the 14 interventional studies, 445 across the 12 observational. Of the 9 that completed or were terminated, 3 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 26 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Research Institute of Geroprotective Technologies as lead sponsor.
Research Institute of Geroprotective Technologies has 1 study filed under Coronary Artery Disease — fewer than ten, so there is no comparison to draw.
10 of the studies in Coronary Artery Disease with a site in Russia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05770349Tomsk National Research Medical Center of the Russian Academy of SciencesUltrastructural Characteristics of Mitochondria in Cardiomyocytes in Heart Failure | 2026-11 |
| NCT04347200National Medical Research Center for Cardiology, Ministry of Health of Russian FederationREGistry of Long-term AnTithrombotic TherApy-1 | 2026-12-31 |
| NCT04347187National Medical Research Center for Cardiology, Ministry of Health of Russian FederationREGistry of Long-term AnTithrombotic TherApy-2 | 2026-12-31 |
| NCT07711106Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health"Expert IVUS-Eye" vs. IVUS-guided Left Main Bifurcation PCI | 2027-01-01 |
| NCT07480915Tomsk National Research Medical Center of the Russian Academy of SciencesRisk Stratification of MACE in Heart Failure Patients Who Undergoing CABG | 2027-03 |
Add all 10 to your calendar (.ics) → With an account.
Among the 26 studies in Coronary Artery Disease with a site in Russia, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an open-label, randomized, multicenter Phase II clinical study designed to evaluate the cardioprotective effect, to determine the optimal dosages and duration of inhalation, and to assess the clinical safety of the medicinal product Aroxxen® in patients undergoing elective percutaneous coronary intervention (PCI) with stent implantation.
Patients who undergo elective PCI are at risk of myocardial injury associated with the procedure. The study aims to assess whether inhalation of Aroxxen®, administered during the procedure and after it, can reduce markers of myocardial damage and improve clinical outcomes, while maintaining an acceptable safety profile.
Eligible patients will be randomized to receive inhalation of Aroxxen® according to the study protocol or standard therapy without inhalation, depending on the assigned group. The study includes multiple centers and compares different dosing regimens and durations of inhalation in order to identify optimal treatment parameters.
Safety will be evaluated by monitoring adverse events, vital signs, and clinical laboratory parameters throughout the study period. The results of this study are intended to provide data on the safety and potential cardioprotective effects of Aroxxen® and to support further clinical development.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receive inhalation of the investigational medicinal product Aroxxen® (composition variant 1) during and after elective percutaneous coronary intervention with stent implantation, according to the study protocol.
Drug: Aroxxen
Patients receive inhalation of the investigational medicinal product Aroxxen® (composition variant 2) during and after elective percutaneous coronary intervention with stent implantation, according to the study protocol.
Drug: Aroxxen
Patients undergo elective percutaneous coronary intervention with stent implantation without additional inhalation of the investigational medicinal product.
Aroxxen® is an investigational medicinal product administered by inhalation during and after elective percutaneous coronary intervention in accordance with the study protocol.
Incremental area under the concentration-time curve (iAUC) of high-sensitivity troponin I (hs-cTnI)
The individual incremental area under the concentration-time curve (iAUC) of high-sensitivity troponin I is calculated for each participant based on serial venous blood measurements obtained at baseline before the start of inhalation and at 4 hours, 12 hours, and 24 hours after the start of inhalation.
Time frame: From baseline before the start of inhalation to 24 hours after the start of inhalation (with assessments at 4, 12, and 24 hours).
Started Mar 2026 (actual). Primary completion is estimated for Oct 2026, 6 months after the start.
Of 26 industry-sponsored phase 2 interventional studies under Coronary Artery Disease, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 29. This study's planned 6 months is below that.
Counting every sponsor, half of 55 studies reached it within 28 months; a quarter within 16 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.